3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
75
Myelodysplastic Syndromes
20
Leukemia, Myelomonocytic, Chronic
10
Myeloproliferative Disorders
5
Hematologic Neoplasms
4
Anemia, Refractory, with Excess of Blasts
4
Recurrence
3
Neoplasms
3
Hematologic Diseases
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
GATA2 Deficiency
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Neurofibromatosis 1
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
ruxolitinib
1
ponatinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Tacrolimus
1
Quality of Life
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Electrocardiography
1
Cyclophosphamide
1
Clinical Laboratory Techniques
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Bone Marrow Examination
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bone Marrow Diseases
×
Azacitidine
×
90 days
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled